- Home
- RBOT vs ADAG Comparison
RBOT vs ADAG Comparison
Compare RBOT & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- ADAG
- Stock Information
- Founded
- RBOT 2014
- ADAG 2011
- Country
- RBOT United States
- ADAG China
- Employees
- RBOT 131
- ADAG N/A
- Industry
- RBOT Medical Specialities
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- RBOT Health Care
- ADAG Health Care
- Exchange
- RBOT Nasdaq
- ADAG Nasdaq
- Market Cap
- RBOT 45.8M
- ADAG 91.4M
- IPO Year
- RBOT N/A
- ADAG 2021
- Fundamental
- Price
- RBOT $8.99
- ADAG $1.83
- Analyst Decision
- RBOT Hold
- ADAG Strong Buy
- Analyst Count
- RBOT 2
- ADAG 1
- Target Price
- RBOT $9.25
- ADAG $8.00
- AVG Volume (30 Days)
- RBOT 11.4K
- ADAG 51.3K
- Earning Date
- RBOT 08-11-2025
- ADAG 07-24-2025
- Dividend Yield
- RBOT N/A
- ADAG N/A
- EPS Growth
- RBOT N/A
- ADAG N/A
- EPS
- RBOT N/A
- ADAG N/A
- Revenue
- RBOT N/A
- ADAG $103,204.00
- Revenue This Year
- RBOT N/A
- ADAG $6,488.89
- Revenue Next Year
- RBOT N/A
- ADAG $57.50
- P/E Ratio
- RBOT N/A
- ADAG N/A
- Revenue Growth
- RBOT N/A
- ADAG N/A
- 52 Week Low
- RBOT $4.27
- ADAG $1.33
- 52 Week High
- RBOT $19.00
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- RBOT 59.44
- ADAG 51.18
- Support Level
- RBOT $7.21
- ADAG $1.74
- Resistance Level
- RBOT $8.30
- ADAG $1.98
- Average True Range (ATR)
- RBOT 0.43
- ADAG 0.12
- MACD
- RBOT 0.05
- ADAG -0.01
- Stochastic Oscillator
- RBOT 99.58
- ADAG 47.22
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.